Charles River Laboratories International, Inc.
CRL
$197.06
$3.211.66%
NYSE
| 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.02B | 4.03B | 4.02B | 4.05B | 4.06B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.02B | 4.03B | 4.02B | 4.05B | 4.06B |
| Cost of Revenue | 2.63B | 2.62B | 2.63B | 2.65B | 2.62B |
| Gross Profit | 1.39B | 1.41B | 1.39B | 1.40B | 1.44B |
| SG&A Expenses | 730.22M | 743.89M | 723.92M | 724.82M | 724.71M |
| Depreciation & Amortization | 124.08M | 129.07M | 132.16M | 127.87M | 120.67M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.49B | 3.50B | 3.49B | 3.50B | 3.46B |
| Operating Income | 535.25M | 532.22M | 533.29M | 549.36M | 597.14M |
| Income Before Tax | -22.20M | -18.15M | 30.08M | 93.11M | 518.61M |
| Income Tax Expenses | 57.43M | 46.73M | 53.39M | 67.82M | 90.62M |
| Earnings from Continuing Operations | -79.62 | -64.88 | -23.31 | 25.29 | 427.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.66M | -2.16M | -1.98M | -3.09M | -4.21M |
| Net Income | -82.28M | -67.04M | -25.29M | 22.20M | 423.78M |
| EBIT | 535.25M | 532.22M | 533.29M | 549.36M | 597.14M |
| EBITDA | 881.99M | 952.99M | 885.14M | 901.70M | 937.29M |
| EPS Basic | -1.55 | -1.31 | -0.63 | 0.17 | 8.04 |
| Normalized Basic EPS | 4.70 | 4.86 | 4.75 | 5.05 | 5.91 |
| EPS Diluted | -1.56 | -1.33 | -0.65 | 0.15 | 7.99 |
| Normalized Diluted EPS | 4.68 | 4.85 | 4.73 | 5.03 | 5.88 |
| Average Basic Shares Outstanding | 200.18M | 202.36M | 204.76M | 205.52M | 205.69M |
| Average Diluted Shares Outstanding | 200.73M | 202.89M | 205.42M | 206.34M | 206.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |